Although SALL4 is rarely mutated (0.1%) in GC, analysis of the TCGA pan-cancer dataset revealed that SALL4 is amplified in GC and other human cancers, including lung squamous cell carcinoma, colon carcinoma, bladder carcinoma, and lung adenocarcinoma (Figure 4C). This evidence concerns the gene SALL4 and urinary bladder carcinoma.